



17W

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:	Philippe G. Nantermet et al.	
Serial No.:	10/573,232	Case No.: 21546YP
US Nat'l Filing Date:	March 23, 2006	
Int'l Appl'n No.	PCT/US2004/032009	
Int'l Filing Date:	29 September 2004	
For:	BENZYLETHER AND BENZYLAMINO BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE	

MAIL STOP PCT
Commissioner for Patents
P.O. BOX 1450
Alexandria, VA 22313-1450


INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR § 1.97

Sir:

In compliance with 37 CFR § 1.97, Applicants and other individuals associated with the filing or prosecution of this application wish to bring to the attention of the Examiner the patents, publications, and other information of which they are aware, listed on the attached form PTO-1449, which they believe may be relevant to the examination of this application or may be material to patentability and in respect of which there may be a duty to disclose in accordance with 37 CFR § 1.56. Applicants respectfully request that the Examiner initial the form PTO-1449 after reviewing the pertinence of each reference.

I hereby certify that this correspondence is being deposited with the United States Postal Services as first class mail in an envelope addressed to: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450, on the date appearing Below.

MERCK & CO., INC.

By:  Date: June 21, 2006

This Information Disclosure Statement is not an admission that any patent, publication, or other information referred to herein is "prior art" for this invention.

In accordance with 37 CFR § 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b). In accordance with 37 CFR § 1.97(g), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made.

Pursuant to 37 CFR § 1.97(b), this Information Disclosure Statement is being filed within three months of the filing date of the present application. Accordingly, it is believed that no fee is due. Any additional fees required in connection with this submission may be taken from Merck Deposit Account No. 13-2755.

Respectfully submitted,

By 
John C. Todaro, Reg. No. 36,036
Attorney for Applicant

MERCK & CO., Inc.
P.O. Box 2000
Rahway, New Jersey 07065-0907
(732) 594-0125

Date: June 21, 2006

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

COMPLETE IF KNOWN

Application Number	10/573,232
Filing Date	March 23, 2006
First Named Inventor	Philippe G. Nantermet
Group Art Unit	To Be Assigned
Examiner Name	To Be Assigned
Attorney Docket Number	21546YP

Sheet

1

of

1

Attorney Docket Number 21546YP

[illegible][illegible]

Examiner
Signature

/Paul Ward/ (12/13/2008)

Date Considered

*Examiner: Initial if reference considered, and if not, citation is in compliance with MPEP 609. Draw line through citation if not in compliance and not considered. Include copy of the form with next communication if applicable.

REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH: /P.W./

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 7/12/2005

Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., -7/12/2005